MedPath

Janssen Inc

🇨🇦Canada
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

11

Active:0
Completed:10

Trial Phases

2 Phases

Phase 2:1
Phase 4:1

Drug Approvals

525

CANADA:262
NMPA:1

Drug Approvals

Prucalopride Succinate Tablets

Product Name
力洛
Approval Number
H20171268
Approval Date
Oct 31, 2017
NMPA

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 2
1 (50.0%)
Phase 4
1 (50.0%)

Golimumab for Adherence in Rheumatoid Arthritis

Completed
Conditions
Arthritis, Rheumatoid
First Posted Date
2018-11-02
Last Posted Date
2024-07-18
Lead Sponsor
Janssen Inc.
Target Recruit Count
222
Registration Number
NCT03729349
Locations
🇨🇦

Peak Medical Specialty Centre, Calgary, Alberta, Canada

🇨🇦

Jacqueline C Stewart Medical Inc., Penticton, British Columbia, Canada

🇨🇦

Dr. Milton F Baker Inc., Victoria, British Columbia, Canada

and more 29 locations

A Study of Participants With Advanced Prostate Cancer in Canada

Completed
Conditions
Prostatic Neoplasms
First Posted Date
2018-04-18
Last Posted Date
2023-07-25
Lead Sponsor
Janssen Inc.
Target Recruit Count
374
Registration Number
NCT03501173
Locations
🇨🇦

Tom Baker Cancer Center, Calgary, Alberta, Canada

🇨🇦

Prostate Cancer Centre, Calgary, Alberta, Canada

🇨🇦

University of Alberta, Edmonton, Alberta, Canada

and more 19 locations

An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada

Completed
Conditions
Diabetes Mellitus, Type 2
First Posted Date
2016-02-23
Last Posted Date
2017-10-30
Lead Sponsor
Janssen Inc.
Target Recruit Count
538
Registration Number
NCT02688075

Observational Study of Golimumab Intravenous Infusion

Terminated
Conditions
Rheumatoid Arthritis
First Posted Date
2015-03-17
Last Posted Date
2016-11-17
Lead Sponsor
Janssen Inc.
Target Recruit Count
78
Registration Number
NCT02390700

A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting

Completed
Conditions
Prostatic Neoplasms
First Posted Date
2015-02-18
Last Posted Date
2019-12-06
Lead Sponsor
Janssen Inc.
Target Recruit Count
194
Registration Number
NCT02364531
  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.